Summit Therapeutics Shares Extend Gains Following AstraZeneca Investment

Key Facts

1Summit Therapeutics shares moved higher Wednesday, extending gains following a $2.0 billion strategic equity investment from AstraZeneca PLC.

2The investment is intended to accelerate the clinical development of ivonescimab.

Summit Therapeutics shares moved higher Wednesday, extending gains following a $2.0 billion strategic equity investment from AstraZeneca PLC. Benzinga reported that the investment is intended to accelerate the clinical development of ivonescimab, a key drug in the company's oncology pipeline.

SMMT closed at $16.39 on September 29, 2026, while AZN was trading at $163.00 on September 30, 2026. AZN reached a session high of $164.484 on September 30, 2026, as the market reacted to the massive capital injection and the long-term potential of the strategic partnership.